Q2 2024 Earnings Forecast for Gilead Sciences, Inc. (NASDAQ:GILD) Issued By Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Zacks Research reduced their Q2 2024 earnings per share estimates for shares of Gilead Sciences in a research note issued on Tuesday, April 23rd. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.40 for the quarter, down from their previous estimate of $1.54. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.55 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.12 EPS, Q1 2026 earnings at $1.43 EPS and FY2026 earnings at $7.18 EPS.

Several other brokerages have also issued reports on GILD. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Mizuho decreased their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Barclays decreased their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Finally, Cantor Fitzgerald reduced their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Stock Up 0.1 %

Shares of NASDAQ:GILD opened at $67.03 on Wednesday. Gilead Sciences has a 52-week low of $65.90 and a 52-week high of $87.86. The firm has a market capitalization of $83.46 billion, a P/E ratio of 14.90, a P/E/G ratio of 0.92 and a beta of 0.19. The stock has a 50 day moving average price of $71.68 and a 200-day moving average price of $76.46. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter last year, the business posted $1.67 EPS. The company’s quarterly revenue was down 3.7% compared to the same quarter last year.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital World Investors boosted its stake in shares of Gilead Sciences by 2.0% in the 4th quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock worth $6,753,350,000 after buying an additional 1,642,736 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Gilead Sciences by 3.0% in the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock worth $4,832,824,000 after buying an additional 1,743,418 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after buying an additional 2,350,550 shares during the last quarter. Morgan Stanley boosted its stake in shares of Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after buying an additional 158,794 shares during the last quarter. Finally, Norges Bank purchased a new position in Gilead Sciences during the fourth quarter valued at $1,301,624,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.59%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.